Stranger in a Strange Land
Chandigarh, India
Joined May 2021
- Tweets849
- Following369
- Followers1.2K
- Likes1.4K
Congratulations to Prof Goel, Prof Shalimar, Prof Aggarwal and the rntire team for a superb pra tice changing work. 💥
8 weeks for #HCV?
In RESOLVE, 8 weeks of sof/vel was non-inferior to 12 weeks in treatment-naive adults without cirrhosis (SVR12: 98.8% vs 99.0%). @ Amit Goel @aiims_newdelhi @SGPGI @kgmu_medical @INASL_Liver @TheLancet
sciencedirect.com/science/ar…
M PREMKUMAR retweeted
🧬 Our new paper in @JCEH_Hepatology is out!
In 69 North Indian MASLD patients genotyped for 12 candidate SNPs, we found that APOC3 and PNPLA3 operate on distinct genetic axes:
🔸 APOC3 rs2854116 — enriched in MASLD vs Indian population (OR 1.93, P<0.001) but NO fibrosis association → susceptibility variant
🔹 PNPLA3 rs738409 — strongest fibrosis predictor (OR 2.89, P=0.006) → severity variant
🔥 Carriers of risk alleles at ALL 3 loci (APOC3+PNPLA3+SAMM50) had 90% fibrosis prevalence (OR 13.7, P=0.0001)
Who gets the disease ≠ who gets worse. Ancestry-specific genetic data matter.
#MASLD #LiverTwitter #Genetics #PNPLA3 #APOC3 #Hepatology #JCEH #IndianGenomics
sciencedirect.com/science/ar…
M PREMKUMAR retweeted
New issue alert ⚠️📙
Dear Readers,
The latest issue Volume 45, Issue 5 of IJG is out. Happy reading 📖🙂
#science #sciencejournal #IJG #ISG #Springer #SpringerNature #journals
link.springer.com/journal/12…
@drvishal82 @DrAnuraagJ @IJG_Journal @UshaPGIMER @drsridhars @docMPK
HCC in GT 3 HCV 🇮🇳
kwnsfk27.r.eu-west-1.awstrac…
De novo HCC post SVR-12 in HCV compensated cirrhosis. was in 128/3994 (3.2%), median follow-up of 4 years, an incidence of 985 per 100,000 person-years; 77.3% men, 71.6% genotype-3, BCLC stages were A (60.2%), B (28.9%), and C (10.9%).
Liver stiffness at SVR-48 (aHR 1.01, 95% CI: 1.001–1.030, P = 0.021) and ALBI score at
SVR-12 (aHR 1.31, 95% CI: 1.1–1.4, P = 0.034) predicted de novo HCC. Recurrence rate ⬇️patientswith de novo HCC than in those with HCC
at presemtation. 5year🇮🇳 cohort. @JCEH_Hepatology
M PREMKUMAR retweeted
Continuing our work on recomp-
1/3rd of AIH also can recomp.
AIH-PBC -25%
AIH-PSC none
link.springer.com/article/10…
@RoyAHep @karanbjmc93 @docMPK @BavenoCoop @ReibergerThomas @JimmyLaiCT @TerryYip12 #LiverX
🚨 Recompensation in decompensated AIH cirrhosis
🔹34% achieved Baveno VII recompensation
🔹 Transplant-free survival was 97% vs 63%* with vs without recompensation
🔹 20% re-decompensated
Recompensation in AIH is real but dynamic.
link.springer.com/article/10…
M PREMKUMAR retweeted
🚨 Recompensation in decompensated AIH cirrhosis
🔹34% achieved Baveno VII recompensation
🔹 Transplant-free survival was 97% vs 63%* with vs without recompensation
🔹 20% re-decompensated
Recompensation in AIH is real but dynamic.
link.springer.com/article/10… – at Kolkata, India
ovid.com/10.1097/HEP.0000000…
Recompensation in MASLD/MetALD spectrum related decompensated cirrhosis with interventions for CMRF control and PEth corroborated alcohol abstinence. #livertwitter @ajay_duseja @nipun verma @AnandVKulkarni2 @BavenoCoop @RoyAHep @shivaramsingh @AASLDtweets
M PREMKUMAR retweeted
🇮🇳 Real-world data from >1000 patients with MASLD/MetALD
MRI-PDFF phenotyping + 🧲 MRE anchor
🔍 Key takeaways:
✔️ Similar CMRF & AF burden
✔️ FIB-4 & NFS perform well
❌ APRI underperforms
💡 Simple NITs even for MetALD
@AnandVKulkarni2 @DrMaheshgoenka
link.springer.com/article/10…
M PREMKUMAR retweeted
🧵NEW STUDY PUBLISHED
Our DiaFib-Liver Study is now published in @LancetRH_SEAsia.
The largest-ever real-world survey of liver fibrosis in type 2 diabetes from any low- or middle-income country.
9,202 patients. 82 doctors. Pan-India. 🇮🇳
🔗 authors.elsevier.com/sd/arti…
M PREMKUMAR retweeted
#Fibrosis prevalence across clinical subgroups:
Highest: CAD (33%),
eGFR <60 (33%),
Obesity (32%),
Dyslipidaemia (30%)
Even without obesity: 19%
Dashed line = overall prevalence (26%).
No difference by sex or hypothyroidism.
Fibrosis is widespread across ALL subgroups.
M PREMKUMAR retweeted
*New Issue Alert*
The special IJG Women and Gastroenterology March-April issue (Volume 45, Issue 2) is online.
Please have a look:
link.springer.com/journal/12…
@IJG_Journal @docMPK @drvishal82 @drsridhars @DrAnuraagJ @giri_gutnliver @UshaPGIMER
M PREMKUMAR retweeted
Gastro-intestinal infections and stewardship practices—A call for action to practising GI professionals
Rohit Gupta et al
link.springer.com/article/10…
M PREMKUMAR retweeted
MUST-READ REVIEW
Gastrointestinal cancers in women: The role of sex hormones
by Amit Yadav &
Prof Usha Dutta @UshaPGIMER
#WomenGI #GItwitter
link.springer.com/article/10…
M PREMKUMAR retweeted
On the occasion of International Women's Day
We released the special issue of @IJG_Journal on women and gastroenterology.
It is purple to signify women empowerment
#GITwitter #WomensDayEveryDay
Please do read and share articles from the Special Isdue on Women in Gastroenterology.... Physicians and Patients. Special thanks to all contributors.@JCEH_Hepatology @IvaKosuta @pummy92 @MaiwallRakhi @SwetaRose3 @ShubhraMishra91 @LisaVWMD @manasa_alla @drvishal82 @drsridhars
Gastroenterology through a gender lens: Clinical and professional perspectives
@docMPK @UshaPGIMER #ProfKochhar
link.springer.com/article/10…
M PREMKUMAR retweeted
🆕 @INASL_Liver Consensus provides practical guidance on “difficult-to-treat AIH”
🔹 Acute AIH
🔹 Cirrhosis
🔹 Overlap syndromes & drug-induced AIH
🔹 Pregnancy, paediatric & post-LT AIH, comorbidities
📖 Read now in JCEH jcehepatology.com/article/S0…
M PREMKUMAR retweeted
Recompensation in ALD-20% (large multicenter data from India)
✅higher in DC without AAH
✅Linked to better survival
Each additional month of abstinence -3% higher chance of recomp.
7% re-decomp
17% decomp further (who did not recomp first)
ghadvances.org/article/S2772…
@BavenoCoop @ReibergerThomas @JimmyLaiCT @RoyAHep @ggarciatsao @ebtapper @juanpabloarab @TCotterMD #LiverX
